Pfizer Inc (PFE): Xtandi prolongs MFS in non-metastatic CR...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	829
Posts	119609
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: None

Thursday, 09/14/2017 9:54:28 AM

Thursday, September 14, 2017 9:54:28 AM

Xtandi prolongs MFS in non-metastatic CRPC:

https://finance.yahoo.com/news/pfizer-astellas-announce-positive-top-090000228.html

Pfizer Inc. and Astellas Pharma…announced today that the Phase 3 PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS). The preliminary safety analysis of the PROSPER trial appears consistent with the safety profile of XTANDI in previous clinical trials.

…Based on the results of PROSPER, the companies intend to discuss the data with global health authorities to potentially support expanding the label for XTANDI to cover all patients with CRPC.

This is pretty big win from a commercial standpoint.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”